You are here

Share:

Search Technologies

Showing 1-20 of 197 results found

Use of Acetalax for Treatment of Triple Negative Breast Cancer

The National Cancer Institute (NCI) seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate). Acetalax is a previously FDA approved drug that has been used as a topical laxative but is being repurposed here as an onco-therapy because of its cytotoxic effects on a number of TNBC and other cancer cell lines.

Platform to Enhance Anti-Tumor Immunity

There is a marked increase in immunosuppressive myeloid progenitors and myeloid cells in tumors and at metastatic tissue sites, rendering these types of cells useful in cancer therapeutics, especially after genetic modifications that improve their anti-tumor properties further. The National Cancer Institute (NCI) seeks research co-development or licensing partners to further develop genetically engineered myeloid cells (GEMys) for use in cancer immunotherapy.

Angiogenesis-Based Cancer Therapeutic

The National Cancer Institute's Urologic Oncology Branch seeks interested parties to co-develop antagonists to VEGF-A and hepatocyte growth factor (HGF) that block signal transduction and associated cellular responses.

Fibroblast Growth Factor Receptor 4 (FGFR4) Monoclonal Antibodies and Methods of Their Use

Researchers at the National Cancer Institute (NCI) developed several high-affinity monoclonal antibodies to treat Fibroblast Growth Factor Receptor 4 (FGFR4)-related diseases including rhabdomyosarcoma and cancers of the liver, lung, pancreas, ovary and prostate. These antibodies have been used to generate antibody-drug conjugates (ADCs) and chimeric antigen receptors (CARs), which are capable of specifically targeting and killing diseased cells. NCI seeks co-development opportunities or licensees for this technology.

A Novel Transgenic Zebrafish Line Reporting Dynamic Epigenetic Changes

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) seeks licensees for a novel “EpiTag” epigenetic reporter transgenic zebrafish line that provides a versatile and powerful whole-animal platform for visualizing and assessing the effects of mutants, experimental treatments, or chemical compounds targeting epigenetic regulation as well as studying epigenetic regulation of global- or tissue-specific gene expression during development.

Margaric Acid Decreases PIEZO2 Mediated Pain

Investigators at the National Center for Complimentary and Integrative Health (NCCIH) and the University of Tennessee Health and Science Center have shown that administration of margaric acid can ameliorate pain induced by a variety of noxious stimuli in mice. In vitro and ex vivo studies in human and murine neural cells indicate that the mechanism of action of margaric acid is mediated by PIEZO2 (Piezo-type mechanosensitive ion channel component 2) function. NCCIH seeks research co-development partners and/or licensees for methods of using the fatty acid, margaric acid to treat pain.

T Cell Receptors (TCRs) Specific for Mutant p53

National Cancer Institute (NCI) researchers have isolated T cell receptors (TCRs) reactive to the highly prevalent p53-R175H mutant in the context of the human leukocyte antigen (HLA) class II allele, HLA-DRB1*13:01. These TCRs can be used for a variety of therapeutic, diagnostic, and research applications. NCI seeks licensing and/or co-development research collaborations for TCRs that recognize the p53-R175H mutation and the associated HLA allele, and methods for identifying p53 mutation-reactive T cell receptors.

Combination of Near Infrared Photoimmunotherapy Targeting Cancer Cells and Host-Immune Activation

Investigators at the National Cancer Institute (NCI) seek co-development partners and/or licensees for a new therapeutic approach that selectively targets cancer cells and prevents tumor regrowth. The novel method combines antibody-IR700 molecules and Near-Infrared Photo Immunotherapy (NIR-PIT), which has shown great potential in targeting tumors via a host immunogenic response, with already known and available anti-cancer immunomodulators to further enhance the antitumor response. The investigators have shown in mouse models that, when used in combination, NIR-PIT-treatment and standard antitumor agents conferred a potent vaccine-like effect, not only curing mice of local and distant cancers but successfully immunizing them against tumor regrowth.

T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias

The National Cancer Institute (NCI) seeks licensees and/or research co-development partners for a collection of T-cell receptors (TCRs) that specifically target the CD20 antigen expressed in B-lymphoid malignancies such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The TCRs are being developed as therapeutics for the treatment of lymphomas and leukemias.

Therapeutic Immunotoxins with Increased Half-Life and Anti-Tumor Activity

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for mesothelin targeting Recombinant Immunotoxins (RITs). These RITs have been engineered by site specific modification with polyethylene glycol (PEG) to have an increased serum half-life, while maintaining high cytotoxicity and have greatly improved anti-tumor activity.

High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors

Researchers at the National Cancer Institute (NCI) have isolated a panel of anti-CD276 (also called B7-H3) single domain antibodies (also known as nanobodies). These antibodies have a high affinity for CD276-positive tumor cells and have great potential for diagnostic and therapeutic technologies against solid tumors. The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies.

Compounds that Interfere with the Androgen Receptor Complex

NCI researchers have identified novel compounds that inhibit FKBP52-mediated activation of the androgen receptor protein (AR), a major target for anti-prostate cancer therapeutic development. As FKBP52 is implicated in the regulation of other hormone receptors, anti-FKBP52 may be applicable in the treatment of hormone-dependent diseases such as diabetes or even used as contraceptives. NCI seeks partners to license or co-develop this technology.

Cell Line for Production of Recombinant Human Tissue Inhibitor of Metalloproteinase-2

Recombinant human tissue inhibitors of metalloproteinases (rhTIMP-2) have been shown to suppress tumor growth and tumor-associated angiogenesis. NCI Radiation Oncology Branch (ROB) researchers have developed a unique HEK-293F cell line which stably expresses rhTIMP-2, increasing the production of TIMP-2 to quantities sufficient to be used for testing and development as a therapeutic for various cancers, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases.

Cancer Vaccine Composed of Oligonucleotides Conjugated to Apoptotic Tumor Cells

Synthetic oligodeoxynucleotides (ODN) containing unmethylated Cytosine-Guanine (CpG) motifs mimic the immunostimulatory activity of bacterial DNA. CpG ODN directly stimulate B cells and plasmacytoid dendritic cells (pDC), promote the production of T Helper 1 cells (Th1) and pro-inflammatory cytokines, and  trigger the maturation/activation of professional antigen presenting cells. The National Cancer Institute, Laboratory of Experimental Immunology, seeks interested parties to license methods for inducing an immune response to tumors.

Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy

Somatic mutations can alter the sensitivity of tumors to T-cell mediated immunotherapy. Identifying genes that positively regulate the sensitivity of cancer cells to T-cell mediated clearance is key for effective treatment in cancer patients. Researchers at the National Cancer Institute (NCI) have identified a panel of genes which are useful in predicting a patient’s response to immunotherapy. NCI seeks partners to co-develop or license the technology toward commercialization.

Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells

Pluripotent stem cells are a promising source of T cells for a variety of clinical applications. However, current in vitro methods of T cell differentiation result in the generation of cells with aberrant phenotypes. Researchers at the National Cancer Institute (NCI) have now developed methodology for generating induced pluripotent stem cell thymic emigrants (iTE). Antigen-specific CD8αβ+ iTEs exhibited functional properties in vitro that were almost indistinguishable from natural naïve CD8αβ+ T cells, including vigorous expansion and robust anti-tumor activity. iTEs recapitulated many of the transcriptional programs of naïve T cells in vivo and revealed a striking capacity for engraftment, memory formation, and efficient tumor destruction. The NCI seeks licensing and/or co-development research collaborations for this invention.

Use of Cucurbitacins and Withanolides for the Treatment of Cancer

The National Cancer Institute's Laboratory of Experimental Immunology, Cancer Inflammation Program, seeks parties interested in collaborative research to co-develop, evaluate, or commercialize the use of certain cucurbatacins or withanolides in combination with pro-apoptotic agonists of TRAIL death receptors for cancer therapy.

Pages